ClinicalTrials.gg
CompletedNCT01868568Updated Oct 22, 2015

Comparison of IDegAsp (Inclusive Three Explorative Formulations) With Insulin Degludec and Insulin Aspart Separately Injected in Subjects With Type 1 Diabetes

A Phase 1 interventional study of insulin degludec and insulin degludec/insulin aspart 30 in Diabetes and Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-10-22.

Primary conditionDiabetes Mellitus, Type 1Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 1
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 1, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing insulin degludec in Diabetes Mellitus, Type 1 — none open to participants now, none under way, none of them phase 3. insulin degludec · Diabetes Mellitus, Type 1.

Enrollment
14th of 39
55 · median 38
Started
2008
with 1 other
Phase 1
24 of 39
none open now
Registered
26th of 39
by date
Lead sponsor
30 of 39
Novo Nordisk A/S

Among the 39 studies testing insulin degludec in Diabetes Mellitus, Type 1, this one is the 14th largest by enrollment, is one of 2 that started in 2008, is one of 24 in phase 1, and was the 26th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

None of the 39 studies testing insulin degludec in Diabetes Mellitus, Type 1 is open now. The open studies under Diabetes Mellitus, Type 1, anywhere →

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies testing insulin degludec in Diabetes Mellitus, Type 1 as a file.
02

Study summary

This trial is conducted in Europe. The aim of this trial is to compare insulin degludec and insulin aspart (IDegAsp) co-formulations with separately injected, simultaneous doses of insulin degludec (insulin 454) and insulin aspart, compared with biphasic insulin aspart 30 (NovoMix® 30) in subjects with type 1 diabetes mellitus. Each subject will be randomised to four out of nine possible treatment arms. IDegAsp 40, IDegAsp 45, IDegAsp 55 and IDeg high concentration were explorative formulations, not similar to the proposed commercial formulation.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 1

Browse trials for

04

In context

Diabetes Mellitus, Type 1 Reclassified

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

This study's enrollment of 55 is above the median of 40 across 2,820 interventional studies indexed under Diabetes Mellitus, Type 1.

Browse Diabetes Mellitus, Type 1 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 1, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Glycosylated (HbA1c) below or equal to 10.0 % based on central laboratory results
  • Diagnosed with type 1 diabetes and treated with insulin for above or equal to 12 months
  • (BMI) between 18.0 and 27.0 kg/m\^2 (both inclusive)

Exclusion criteria

Exclusion Criteria:

  • A subject with a history of significant multiple drug allergies or with a known or suspected allergy to the trial product or any medicine chemically related to the trialproduct, as judged by the Investigator
  • A subject who is known to have hepatitis or who is carrier of the surface antibodies, or has a positive result to the test for antigen (HBsAg) or antibodies
  • A subject who has participated in any other trials involving products within the 3 months preceding the start of dosing
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    IDegAsp 30 + placebo

    Drug: insulin degludec/insulin aspart 30 · Drug: placebo

  • Experimental
    Insulin aspart + insulin degludec - low concentration 1

    Drug: insulin degludec · Drug: insulin aspart

  • Experimental
    IDegAsp 40 + placebo

    Drug: insulin degludec/insulin aspart 40 · Drug: placebo

  • Experimental
    Insulin aspart + insulin degludec - high concentration 1

    Drug: insulin degludec · Drug: insulin aspart

  • Experimental
    IDegAsp 45 + placebo

    Drug: insulin degludec/insulin aspart 45 · Drug: placebo

  • Experimental
    Insulin aspart + insulin degludec

    Drug: insulin degludec · Drug: insulin aspart

  • Experimental
    IDegAsp 55 + placebo

    Drug: insulin degludec/insulin aspart 55 · Drug: placebo

  • Experimental
    Insulin aspart + insulin degludec - high concentration

    Drug: insulin degludec · Drug: insulin aspart

  • Active comparator
    BIAsp 30 + placebo

    Drug: biphasic insulin aspart 30 · Drug: placebo

Interventions

  • Administered subcutaneously (s.c., under the skin).

  • Druginsulin degludec/insulin aspart 30

    A single dose administered subcutaneously (s.c., under the skin).

  • Druginsulin degludec/insulin aspart 40

    A single dose administered subcutaneously (s.c., under the skin).

  • Druginsulin degludec/insulin aspart 45

    A single dose administered subcutaneously (s.c., under the skin).

  • Druginsulin degludec/insulin aspart 55

    A single dose administered subcutaneously (s.c., under the skin).

  • A single dose administered subcutaneously (s.c., under the skin).

  • Drugbiphasic insulin aspart 30

    A single dose administered subcutaneously (s.c., under the skin).

  • Drugplacebo

    A single dose administered subcutaneously (s.c., under the skin).

07

What researchers measure

Primary outcomes

  1. Area under the insulin aspart concentration curve

    Time frame: 0-2 hours after dosing

Secondary outcomes

  1. Area under the glucose infusion rate curve

    Time frame: 0-26 hours after dosing

  2. Area under the serum insulin 454 concentration curve

    Time frame: 0-120 hours after dosing

08

Study locations

1 site
  • Neuss, 41460, Germany
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2013
First posted
Jun 4, 2013
Start
Apr 2008
Primary completionActual
Aug 2008
CompletionActual
Aug 2008
Last update
Oct 22, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01868568
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jun 4, 2013
Start date
Apr 2008
Primary completion
Aug 2008
Completion
Aug 2008
Last update
Oct 22, 2015

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin degludec · Insulin Aspart

Start the discussion